Griseofulvin is FDA approved for and the drug of choice in tinea capitis. Other indications include onychomycosis as well as superficial fungal infections resistant to topical antifungal medications. This activity will highlight the mechanism of action, adverse event profile, monitoring, and relevant interactions of griseofulvin, pertinent for members of the interprofessional team in the treatment of patients with the conditions mentioned above when using griseofulvin.

**Objectives:**
- Describe the therapeutic mechanism of action of griseofulvin.
- Summarize the organisms for which griseofulvin is an indicated therapy.
- Outline the contraindications and adverse events associated with griseofulvin therapy.
- Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients who can benefit from therapy with griseofulvin.